Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

50.61 +0.71 (+1.42%)

Streaming Delayed Price Updated: 2:02 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

36 37 Next >

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

January 30, 2026

Opportunity knocks thrice for the iconic growth investor.

Via The Motley Fool

Topics Artificial Intelligence

Forget AI Stocks: This Biotech Could Cure What AI Can't Touch ↗

January 29, 2026

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

Via The Motley Fool

Topics Artificial Intelligence

Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗

January 29, 2026

Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits.

Via Stocktwits

Topics Artificial Intelligence ETFs Government

Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops ↗

January 27, 2026

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core...

Via Benzinga

Retail Bulls Call CRISPR ‘Criminally Undervalued’ After Gene-Editing Breakthrough Cuts Cholesterol By 70% ↗

November 10, 2025

Via Stocktwits

2 Biotech Stocks That Could Soar This Year ↗

January 12, 2026

And, if all goes well, over the next five years as well.

Via The Motley Fool

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026? ↗

December 26, 2025

There are some risks to consider before jumping on the bandwagon.

Via The Motley Fool

The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy

December 24, 2025

On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),...

Via PredictStreet

Topics Economy

Is CRISPR Therapeutics Stock Yesterday's News? ↗

December 24, 2025

The biotech sells blood disorders treatment, Casgevy.

Via The Motley Fool

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗

December 23, 2025

All three companies' businesses are on the verge of long-term growth explosions.

Via The Motley Fool

Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? ↗

December 19, 2025

Next year could be crucial for the company as sales for its only approved treatment could take off.

Via The Motley Fool

2 Growth Stocks to Invest $1,000 in Right Now ↗

December 18, 2025

These stocks have promising assets in their portfolios that could help make their valuations soar in the future.

Via The Motley Fool

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

December 16, 2025

Issued on behalf of Avant Technologies Inc.

From USA News Group

Via GlobeNewswire

2 Monster Stocks in the Making to Buy and Hold ↗

December 16, 2025

The next 12 months will tell us more about their prospects.

Via The Motley Fool

12 Days of Investing: My Top 12 Stocks to Buy Before 2026 ↗

December 15, 2025

The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.

Via The Motley Fool

Topics Artificial Intelligence

2 Healthcare Stocks to Buy Ahead of the New Year ↗

December 12, 2025

These companies could innovate their way to success.

Via The Motley Fool

2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗

December 07, 2025

This juicy upside potential comes at a cost.

Via The Motley Fool

Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% ↗

November 30, 2025

This company's first product has started to generate revenue.

Via The Motley Fool

Topics ETFs

The Best Stocks to Buy With $1,000 Right Now ↗

November 29, 2025

It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction.

Via The Motley Fool

Topics Artificial Intelligence Energy

3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential ↗

November 21, 2025

These stocks have market caps of around $4 billion and $5 billion, and they could potentially double or triple in size in the long run.

Via The Motley Fool

Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results

November 19, 2025

Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of...

Via MarketMinute

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

November 19, 2025

These stocks both have advanced in the double-digits in recent months.

Via The Motley Fool

1 Underrated Stock That Could Soar by 58%, According to Wall Street ↗

November 17, 2025

This biotech has already made impressive contributions to medicine, and it could make more. But does that make it a buy?

Via The Motley Fool

ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried? ↗

November 12, 2025

ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried?

Via The Motley Fool

Topics Regulatory Compliance

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗

November 11, 2025

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform.

Via Benzinga

The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market

November 14, 2025

The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Why Gene-Editing Giants Crispr And Intellia Just Surged ↗

November 10, 2025

The companies are working on one-and-done treatments for diseases tied to genetic problems.

Via Investor's Business Daily

Topics Death

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗

November 07, 2025

The company remains confident in its other gene-editing product, which would treat a swelling disorder.

Via Investor's Business Daily

Topics Death

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as...

Via TokenRing AI

Topics Artificial Intelligence Climate Change Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.